ACADIA Pharmaceuticals (ACAD)
(Delayed Data from NSDQ)
$14.85 USD
-0.27 (-1.79%)
Updated May 16, 2024 04:00 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ACAD 14.85 -0.27(-1.79%)
Will ACAD be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ACAD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACAD
Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings Estimates
ACAD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ligand Pharmaceuticals (LGND) Tops Q1 Earnings Estimates
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?
Other News for ACAD
Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
Cantor picks 14 undervalued biotech stocks worth a second look
Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), ACADIA Pharmaceuticals (ACAD) and Disc Medicine (IRON)
Buy Rating for ACADIA Pharmaceuticals Based on Promising Drug Prospects and Financial Stability
ACADIA Pharmaceuticals Q1 2024 Earnings: Solid Growth with New Product Launches